Miravant Plans Photrex Confirmatory Macular Degeneration Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The trial, to be conducted under a special protocol assessment with FDA, will be one year with another year for confirmatory results. Agency's September 2004 "approvable" letter for the photodynamic therapy requested an additional study. Miravant is also planning combination studies with other age-related macular degeneration agents.
You may also be interested in...
Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label
The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.
Miravant's SnET2 Requires Additional Clinical Trial For Macular Degeneration
FDA needs further confirmation before granting full approval to the photosensitive drug/photodynamic therapy combination, Miravant says. The firm is seeking approval for both predominantly and minimally classic AMD.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).